This inventor holds 1 USPTO granted patent. Top assignees: Breast Cancer Now, The Institute of Cancer Research: Royal Cancer Hospital. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 2 
1 out of 54 
Years Active: 2025
Title: Samuel Jones - Innovator in Cancer Treatment
Introduction
Samuel Jones is a notable inventor based in London, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of therapeutic methods.
Latest Patents
Samuel Jones holds a patent for "Inhibitors of Ataxia-Telangiectasia Mutated and Rad3-related protein kinase (ATR) for use in methods of treating cancer." This invention relates to ATR inhibitors that are utilized in treating BAF-complex deficient cancers. The patent also outlines methods for identifying ATR inhibitors specifically for BAF complex gene mutant or deficient cancers. Additionally, it provides medical uses and methods for treating synovial sarcoma using ATR inhibitors.
Career Highlights
Throughout his career, Samuel has worked with esteemed organizations such as the Institute of Cancer Research and Breast Cancer Now. His work has focused on advancing cancer treatment methodologies and improving patient outcomes.
Collaborations
Samuel has collaborated with notable colleagues, including Christopher James Lord and Chris Williamson, contributing to the advancement of cancer research and treatment.
Conclusion
Samuel Jones is a pioneering inventor whose work in developing ATR inhibitors represents a significant advancement in cancer treatment. His contributions continue to impact the medical field positively.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile